Table 2. Proteins that differed significantly between aspirin and placebo periods with false discovery rate (FDR) <0.10.
| Symbol | Functiona | Missing%b | Average expressionc | Effect sized | Fold changee | p-valuef | Adjusted p-valueg | |
|---|---|---|---|---|---|---|---|---|
| aspirin | placebo | |||||||
| SDHC | Conservative effector of mitochondrial Krebs cycle and respiratory chain | 20.5 | -0.259 | -0.112 | -0.594 | 0.662 | 4.47×10−05 | 0.058 |
| MYH1 | Energy convertor in base excision repair (BER) pathway | 18.2 | -0.262 | -0.454 | 0.698 | 1.622 | 6.83×10−05 | 0.058 |
| NR2F1 | Nuclear hormone receptor and transcriptional regulator | 11.4 | -0.371 | -0.265 | -0.755 | 0.592 | 6.94×10−05 | 0.058 |
| FOXO1 | Transcription factor in carbohydrates metabolism and Akt-mTOR signaling pathway | 17.0 | 1.003 | 0.845 | 0.520 | 1.434 | 7.72×10−05 | 0.058 |
| KHDRBS3 | RNA-binding protein regulating pre-mRNA splicing, signaling and cell cycle control | 27.3 | 0.096 | -0.028 | 0.400 | 1.320 | 2.07×10−04 | 0.087 |
| NFKBIE | NF-κB inhibitor epsilon | 23.9 | 0.530 | 0.374 | 0.709 | 1.634 | 2.15×10−04 | 0.087 |
| LYZ | Lysozyme, antimicrobial enzyme | 26.1 | 0.004 | -0.147 | 0.689 | 1.612 | 2.29×10−04 | 0.087 |
| MSI1 | RNA-binding protein, posttranscriptional regulator of proliferative activity | 26.1 | -0.351 | -0.176 | -0.487 | 0.714 | 2.32×10−04 | 0.087 |
| IKZF1 | Transcription factor of zinc-finger DNA-binding and lymphocyte differentiation regulator | 4.5 | -0.310 | -0.426 | 0.542 | 1.456 | 2.67×10−04 | 0.089 |
a Information pertaining to encoded protein function was derived from PubMed Gene unless otherwise noted.
b Missing% is the proportion of samples with missing values on this protein among all 88 samples.
c Average expression level was presented in median M values for each protein.
d Effect size was the mean difference of M values between two treatment periods standardized by standard deviation of average expression in placebo period.
e Fold-change was the standardized ratio between median M values of aspirin and placebo treatment. A fold change >1 indicated greater antibody expression after aspirin treatment compared to placebo; a fold change <1 indicated lower expression after aspirin treatment.
f P-values were obtained from mixed linear regression model, adjusted for batch effect, sample position, gender and genotype.
g P-values were adjusted for false discovery rate using Benjamini-Horchberg procedure.